

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

December 20, 2023

Kory Wentworth Chief Financial Officer Entrada Therapeutics, Inc. One Design Center Place Suite 17-500 Boston, MA 02210

> Re: Entrada Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 6, 2023 File No. 001-40969

Dear Kory Wentworth:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Life Sciences